{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:25:41Z","timestamp":1774308341992,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>There is no evidence regarding the effect of ondansetron on the QT interval in pediatric patients in the ICU. This study aimed to describe the effect of ondansetron on the corrected QT interval in patients cared for in the PICU.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Retrospective cohort, consecutive enrollment study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Single-center, tertiary-level, medical\/surgical PICU.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>All patients less than 8 years old who received ondansetron over an 11-month period were included. Exclusion criteria were atrial arrhythmia, bundle-branch block, known congenital long QT syndrome, and concomitant administration of proarrhythmic antiarrhythmic agents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>Overall, 210 doses of ondansetron were administered to 107 patients, with a mean age 10.5\u2009\u00b1\u20094.8 years; 49% were men. Corrected QT interval increased to 460\u2013500\u2009ms in 29% and to more than 500\u2009ms in 11% of events of ondansetron administration. The mean baseline corrected QT interval even before ondansetron administration was higher for these groups (460\u2013500 and &gt; 500\u2009ms; 457\u2009\u00b1\u200933 and 469\u2009\u00b1\u200945, respectively; <jats:italic toggle=\"yes\">p<\/jats:italic> \u2264 0.05). In multivariate analysis, both groups were associated significantly with underlying electrolyte abnormalities (odds ratio, 2.2; 95% CI, 1.1\u20134.4 and odds ratio, 5.1; 95% CI, 1.8\u201315.7, respectively); the group with corrected QT interval more than 500\u2009ms was also significantly associated with organ dysfunction (odds ratio, 3.2; 95% CI, 1.1\u20139.4). As the numbers of risk factors increased from only ondansetron to three additional QT aggravating factors (electrolyte abnormalities, administration of other QT-prolonging drugs, and organ dysfunction), the likelihood of being associated with corrected QT interval more than 500\u2009ms increased.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Prolonged QT interval is observed commonly in PICUs following the administration of ondansetron. Underlying risk factors, such as electrolyte abnormalities and organ dysfunction, seem to pose the highest risk of prolongation of QT interval in these patients. The awareness of prevalent risk factors for increased corrected QT interval may help identify patients at high risk for arrhythmias.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pcc.0000000000000776","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T16:37:11Z","timestamp":1467995831000},"page":"e317-e323","source":"Crossref","is-referenced-by-count":15,"title":["Effect of Ondansetron on QT Interval in Patients Cared for in the PICU"],"prefix":"10.1097","volume":"17","author":[{"given":"Sangita","family":"Trivedi","sequence":"first","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Schiltz","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Kanipakam","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan Martijn","family":"Bos","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Ouellette","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230823","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","article-title":"QT interval: How to measure it and what is \u201cnormal\u201d.","volume":"17","author":"Goldenberg","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R3-20230823","first-page":"614","article-title":"Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.","volume":"295","author":"Kuryshev","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"R6-20230823","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation.","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"key":"R7-20230823","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1097\/CCM.0b013e3181de112a","article-title":"Drug-induced arrhythmias.","volume":"38","author":"Barnes","year":"2010","journal-title":"Crit Care Med"},{"issue":"4 suppl","key":"R9-20230823","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.jelectrocard.2006.05.018","article-title":"An algorithm for continuous real-time QT interval monitoring.","volume":"39","author":"Helfenbein","year":"2006","journal-title":"J Electrocardiol"},{"key":"R10-20230823","first-page":"9","article-title":"Ondansetron metabolism and pharmacokinetics.","volume":"19","author":"Pritchard","year":"1992","journal-title":"Semin Oncol"},{"key":"R12-20230823","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/pds.1707","article-title":"Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.","volume":"18","author":"Lin","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R13-20230823","doi-asserted-by":"crossref","first-page":"23B","DOI":"10.1016\/0002-9149(93)90036-C","article-title":"Measurement of the QT interval and the risk associated with QTc interval prolongation: A review.","volume":"72","author":"Moss","year":"1993","journal-title":"Am J Cardiol"},{"key":"R16-20230823","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval.","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"R17-20230823","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2796.2005.01589.x","article-title":"Long QT syndrome: Reduced repolarization reserve and the genetic link.","volume":"259","author":"Roden","year":"2006","journal-title":"J Intern Med"},{"key":"R18-20230823","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.coc.0000144849.41300.0a","article-title":"The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.","volume":"28","author":"Buyukavci","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"R19-20230823","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/pan.12339","article-title":"The effect of sevoflurane and ondansetron on QT interval and transmural dispersion of repolarization in children.","volume":"24","author":"Lee","year":"2014","journal-title":"Paediatr Anaesth"},{"key":"R20-20230823","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1460-9592.2010.03408.x","article-title":"The effects of droperidol and ondansetron on dispersion of myocardial repolarization in children.","volume":"20","author":"Mehta","year":"2010","journal-title":"Paediatr Anaesth"},{"key":"R21-20230823","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2125.2006.02722.x","article-title":"In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs.","volume":"63","author":"De Bruin","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20230823","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HCO.0b013e32801129eb","article-title":"Drug-induced long QT and torsade de pointes: Recent advances.","volume":"22","author":"Kannankeril","year":"2007","journal-title":"Curr Opin Cardiol"},{"key":"R23-20230823","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pds.1155","article-title":"Frequency of high-risk use of QT-prolonging medications.","volume":"15","author":"Allen LaPointe","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R24-20230823","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/01.md.0000085057.63483.9b","article-title":"Torsade de pointes due to noncardiac drugs: Most patients have easily identifiable risk factors.","volume":"82","author":"Zeltser","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"R25-20230823","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1001\/jama.1993.03510210076031","article-title":"Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.","volume":"270","author":"Makkar","year":"1993","journal-title":"JAMA"},{"key":"R26-20230823","first-page":"690","article-title":"Sex differences in the evolution of the electrocardiographic QT interval with age.","volume":"8","author":"Rautaharju","year":"1992","journal-title":"Can J Cardiol"},{"key":"R27-20230823","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1161\/01.CIR.97.22.2237","article-title":"Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry.","volume":"97","author":"Locati","year":"1998","journal-title":"Circulation"},{"key":"R28-20230823","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/01.CIR.96.7.2149","article-title":"Normalization of acquired QT prolongation in humans by intravenous potassium.","volume":"96","author":"Choy","year":"1997","journal-title":"Circulation"},{"key":"R29-20230823","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0002-9343(87)90128-8","article-title":"Effects of low potassium or magnesium concentrations on isolated cardiac tissue.","volume":"82","author":"Roden","year":"1987","journal-title":"Am J Med"},{"key":"R30-20230823","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0002-9149(84)90025-0","article-title":"Magnesium therapy for torsades de pointes.","volume":"53","author":"Tzivoni","year":"1984","journal-title":"Am J Cardiol"},{"key":"R31-20230823","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0002-9149(02)03423-9","article-title":"Effects of calcium treatment on QT interval and QT dispersion in hypocalcemia.","volume":"91","author":"Eryol","year":"2003","journal-title":"Am J Cardiol"},{"key":"R32-20230823","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1046\/j.1523-1755.2000.00062.x","article-title":"QTc dispersion increases during hemodialysis with low-calcium dialysate.","volume":"57","author":"N\u00e4ppi","year":"2000","journal-title":"Kidney Int"},{"key":"R33-20230823","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jpeds.2014.12.037","article-title":"Comparison of formulas for calculation of the corrected QT interval in infants and young children.","volume":"166","author":"Phan","year":"2015","journal-title":"J Pediatr"},{"key":"R34-20230823","first-page":"1","article-title":"The QT interval.","volume":"43","author":"Bednar","year":"2001","journal-title":"Prog Cardiovasc Dis"},{"key":"R35-20230823","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1540-8167.2004.03534.x","article-title":"Drug-induced torsades de pointes and implications for drug development.","volume":"15","author":"Fenichel","year":"2004","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130478-201607000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T23:02:59Z","timestamp":1692831779000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130478-201607000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000000776","relation":{},"ISSN":["1529-7535"],"issn-type":[{"value":"1529-7535","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}